One Biosciences
France · Biotech
Single-cell tumour profiling for oncology teams and pharma and biotech partners, turning routine biopsy samples into clinical insights for treatment selection and drug development.
A fuller picture from routine tumour samples
OneMap combines proprietary preparation protocols for formalin-fixed or frozen samples, single-nucleus RNA sequencing and AI analysis. It profiles tumour, stromal and immune cells to reveal tumour-cell states, target expression and immune function that bulk sequencing can obscure; the company says its clinical-grade reports are delivered in under two weeks.
For clinical decisions and drug development
Oncology teams can use the reports for patient-level treatment selection, while pharmaceutical and biotechnology partners use the same single-cell view to identify predictive biomarkers, stratify trial participants, assess response and prioritize targets. One Biosciences describes its platform as clinically validated across multiple tumour types; its first diagnostic for triple-negative breast cancer was still in development with Institut Curie in the September 2026 funding announcement.
- Headquarters
- Paris, France
- Product maturity
- Commercial clinical-grade profiling and partnering platform; first TNBC diagnostic in development.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| i-Démo 5 grant (France 2030) | €3.3M | Bpifrance — Participant |